Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. CVM
CVM logo

CVM Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
3.870
Open
3.650
VWAP
3.72
Vol
10.33K
Mkt Cap
31.29M
Low
3.610
Amount
38.44K
EV/EBITDA(TTM)
--
Total Shares
8.46M
EV
32.42M
EV/OCF(TTM)
--
P/S(TTM)
--
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Show More

Events Timeline

(ET)
2025-08-27
23:44:20
CEL-SCI Prices 1.11M Share Spot Secondary Offering at $9.00
select
2025-08-27
17:28:06
CEL-SCI reveals common stock offering, amount unspecified
select
2025-08-14 (ET)
2025-08-14
10:47:54
CEL-SCI reports Q3 EPS ($1.36) vs. ($4.18) last year
select
2025-08-13 (ET)
2025-08-13
09:22:51
CEL-SCI files for breakthrough designation for Multikine in Saudi Arabia
select
2025-07-11 (ET)
2025-07-11
12:22:42
CEL-SCI announces pricing of $5.7M at-the-market common stock offering
select
2025-07-11
09:22:45
CEL-SCI teams with Saudi Arabia pharmaceutical, healthcare company for Multikine
select
2025-05-21 (ET)
2025-05-21
20:37:55
CEL-SCI 2M share Spot Secondary priced at $2.50
select
2025-05-21
16:07:07
CEL-SCI announces common stock offering, no amount given
select
2025-05-21
08:03:18
CEL-SCI completes Breakthrough Medicine Designation application for Multikine
select

News

seekingalpha
9.5
02-18seekingalpha
Cel-Sci Reports Q1 2025 Financial Results with Significant Losses
  • Earnings Per Share Loss: Cel-Sci reported a GAAP EPS of -$0.68 for Q1 2025, indicating significant challenges in profitability that could impact investor confidence moving forward.
  • R&D Expense Decline: Research and development expenses totaled $3.7 million this quarter, down from $4.4 million in Q4 2024, suggesting the company may be implementing cost-control measures, which could affect future product development timelines.
  • Administrative Expense Reduction: General and administrative expenses decreased to $1.7 million in Q1 2025 from $2.5 million in Q4 2024, reflecting improvements in operational efficiency, although the overall financial situation remains precarious.
  • Net Loss Overview: The net loss for the quarter was $5.5 million, a reduction from $7.1 million in the prior year period, indicating the company is making efforts to reduce losses while still facing a challenging market environment.
stocktwits
8.5
01-26stocktwits
Cel-Sci CEO Buys Shares, Stock Rises 7%
  • CEO Share Purchase: Cel-Sci's CEO Geert R. purchased 38,023 shares at $5.26 each on January 22 for approximately $200,000, increasing his total holdings to 120,815 shares, reflecting confidence in the company's future prospects.
  • Clinical Trial Preparation: The company is preparing for a confirmatory registration study for its experimental cancer treatment Multikine, aiming to enroll 212 patients with newly diagnosed resectable head and neck cancer, with enrollment expected to begin in spring 2026 and potential approval by 2028 based on generated data.
  • Improved Financial Performance: For the fiscal year ending in September, Cel-Sci reported a net loss of $25.4 million, down from $27.6 million in fiscal 2024, indicating efforts to control costs and improve financial health.
  • Positive Market Sentiment: On Stocktwits, retail sentiment around CVM stock remained in the 'bullish' territory, with message volume rising from 'high' to 'extremely high', suggesting investor optimism about the company's future developments.
Newsfilter
2.0
2025-12-29Newsfilter
CEL-SCI Files for Breakthrough Designation for Multikine in Saudi Arabia, Plans 212-Patient Enrollment in 2026
  • Clinical Trial Progress: CEL-SCI is preparing for a 212-patient Confirmatory Registration Study for newly diagnosed head and neck cancer patients, with enrollment expected to begin in Spring 2026, paving the way for potential early approval in the U.S. and significantly enhancing market competitiveness.
  • Survival Rate Improvement: Multikine demonstrated a long-term survival rate of 73% in prior Phase 3 studies compared to 45% in the control group, significantly reducing the risks associated with developing cancer therapies and boosting investor confidence.
  • Market Expansion in Saudi Arabia: CEL-SCI has applied for Breakthrough Medicine Designation in Saudi Arabia and is collaborating with a local company to support the Kingdom's Vision 2030, further solidifying its leadership position in the global biotechnology sector.
  • Financial Condition Improvement: As of September 30, 2025, CEL-SCI's net loss decreased to $25.4 million, with R&D expenses down 13%, reflecting the company's proactive efforts in cost control and resource optimization.
NASDAQ.COM
2.0
2025-09-19NASDAQ.COM
Emerging Growth Stocks Experience Significant Gains in After-Hours Trading
  • Adaptimmune Therapeutics Surge: Adaptimmune Therapeutics plc (ADAP) saw a dramatic after-hours increase of 30% following a nearly 98% gain during regular trading, driven by renewed investor interest despite no specific news. The company reported a net loss of $30.3 million for Q2 2025 but has made strategic moves, including selling cell therapies for $55 million.

  • Butterfly Network Recognition: Butterfly Network Inc. (BFLY) rose 10.58% in after-hours trading after being named one of TIME's Top HealthTech Companies for 2025, alongside a recent appointment of a new CTO. The company’s technology has been validated by a JAMA study showing significant reductions in hospital stays and costs.

  • Aquestive Therapeutics Positive Outlook: Aquestive Therapeutics Inc. (AQST) continued its upward trend with a 7.69% increase in after-hours trading, bolstered by FDA confirmation that no advisory committee meeting is needed for its NDA for Anaphylm, streamlining the approval process. The company also secured $75 million in strategic funding.

  • Insider Confidence at ALX Oncology: ALX Oncology Holdings Inc. (ALXO) gained 9.17% in after-hours trading, attributed to insider buying by CEO Jason Lettmann, signaling confidence in the company. ALXO's lead candidate, Evorpacept, is currently in multiple clinical trials, maintaining investor interest despite no new data releases.

Benzinga
4.5
2025-08-28Benzinga
Stock Market Update: Nvidia Weighs on Nasdaq Futures—Attention on Dollar General, Dell, and Best Buy
  • Market Overview: U.S. stock futures showed mixed results following gains from the previous day, with Nvidia Corp. experiencing a decline despite reporting better-than-expected second-quarter results.

  • Nvidia's Performance: Nvidia's stock fell due to lack of guidance on H20 shipments to China and weaker data center revenue, although analysts remain optimistic about its leadership in AI infrastructure.

  • Economic Indicators: The 10-year Treasury bond yield was at 4.23%, with markets anticipating an 87.3% chance of interest rate cuts by the Federal Reserve in September; mortgage applications also saw a slight decline.

  • Stock Movements: Notable stock movements included MongoDB Inc. rising 38% after strong earnings, while Kohl’s Corp. gained 24%. Conversely, CEL-SCI Corp. dropped 30.83% after announcing a public offering.

Benzinga
9.5
2025-08-28Benzinga
Snowflake Shares Surge 14%; Check Out 20 Stocks Making Moves in Premarket Trading
  • Snowflake Inc. Financial Results: Snowflake's shares surged 14.2% in pre-market trading after reporting second-quarter revenue of $1.14 billion and adjusted earnings of 35 cents per share, both exceeding analyst expectations.

  • Other Gainers in Pre-Market Trading: Several stocks saw significant gains, including Erayak Power Solution Group (up 52.5%), Top KingWin Ltd (up 50.5%), and Telomir Pharmaceuticals (up 43.9%).

  • Notable Losers in Pre-Market Trading: CEL-SCI Corporation experienced a sharp decline of 29.8% following a public offering announcement, while The Cooper Companies and Cognition Therapeutics also reported losses of 14.5% and 14.1%, respectively.

  • NVIDIA's Performance: NVIDIA shares fell 2% despite reporting better-than-expected earnings and projecting third-quarter revenue within the consensus estimate range.

Valuation Metrics

The current forward P/E ratio for CEL-SCI Corp (CVM.A) is -1.47, compared to its 5-year average forward P/E of -8.39. For a more detailed relative valuation and DCF analysis to assess CEL-SCI Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.39
Current PE
-1.47
Overvalued PE
5.08
Undervalued PE
-21.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.97
Current EV/EBITDA
-1.86
Overvalued EV/EBITDA
1.78
Undervalued EV/EBITDA
-11.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
266.98
Current PS
4.62
Overvalued PS
964.15
Undervalued PS
-430.20

Financials

AI Analysis
Annual
Quarterly

Whales Holding CVM

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is CEL-SCI Corp (CVM) stock price today?

The current price of CVM is 3.685 USD — it has decreased -0.41

What is CEL-SCI Corp (CVM)'s business?

CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).

What is the price predicton of CVM Stock?

Wall Street analysts forecast CVM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is CEL-SCI Corp (CVM)'s revenue for the last quarter?

CEL-SCI Corp revenue for the last quarter amounts to 0.00 USD, decreased

What is CEL-SCI Corp (CVM)'s earnings per share (EPS) for the last quarter?

CEL-SCI Corp. EPS for the last quarter amounts to -0.68 USD, decreased -79.08

How many employees does CEL-SCI Corp (CVM). have?

CEL-SCI Corp (CVM) has 44 emplpoyees as of March 12 2026.

What is CEL-SCI Corp (CVM) market cap?

Today CVM has the market capitalization of 31.29M USD.